The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 347:614-615 August 22, 2002 Number 8
NextNext

Erythromycin-Resistant Group A Streptococci

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
 by Huovinen, P.
-Related Article
 by Martin, J. M.
-PubMed Citation
To the Editor: Martin et al. (April 18 issue)1 identified the emergence of a clone of macrolide-resistant group A streptococci among schoolchildren in Pittsburgh. We are concerned that, on the basis of this finding, physicians will unnecessarily choose even broader-spectrum antimicrobial agents for the treatment of pharyngitis caused by group A streptococci.

Our analysis of data collected in the National Ambulatory Medical Care Survey from 1989 to 1999 showed a significant increase in the use by primary care physicians of extended-spectrum macrolides (mostly clarithromycin and azithromycin) for adults with sore throat.2 This increase probably provides the selective pressure necessary for . . . [Full Text of this Article]


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.